

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease ID6459**

**Provisional Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>Ferrer International (inhaled treprostinil)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>Action for Pulmonary Fibrosis</li> <li>Asthma and Lung UK</li> <li>British Cardiovascular Society</li> <li>Cardiovascular Care Partnership</li> <li>Heart UK</li> <li>NARA - The Breathing Charity</li> <li>Pulmonary Hypertension Association UK</li> <li>Pumping Marvellous Foundation</li> <li>Scleroderma &amp; Raynaud's UK</li> <li>Somerville Foundation</li> <li>Specialised Healthcare Alliance</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>Association of Respiratory Nurse Specialists</li> <li>Association for Respiratory Technology and Physiology</li> <li>British Association for Nursing in Cardiovascular Care</li> <li>British Geriatrics Society</li> <li>British Heart Foundation</li> <li>British Nuclear Cardiology Society</li> <li>British Society for Haematology</li> <li>British Society for Heart Failure</li> <li>British Society of Cardiovascular Imaging</li> <li>British Thoracic Society</li> <li>ENT UK</li> <li>ILD-IN: Interstitial Lung Diseases Interdisciplinary Network</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health - Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Welsh Government</li> <li>Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>Amarox (sildenafil)</li> <li>Aurobindo Pharma – Milpharm (sildenafil)</li> <li>Brown and Burk UK (tadalafil)</li> <li>Eli Lilly (tadalafil)</li> <li>Mylan (tadalafil)</li> <li>Pfizer (sildenafil)</li> <li>Rosemont Pharmaceuticals (sildenafil)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>British Association for Lung Research</li> <li>British Society for Cardiovascular Research</li> <li>Cardiac and Cardiology Research Dept, Barts</li> </ul>

Provisional stakeholder list for the evaluation of inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease ID6459

Issue date: March 2025

© National Institute for Health and Care Excellence 2025. All rights reserved. 1 of 3

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• National Heart and Lung Institute</li> <li>• Primary Care Cardiovascular Society</li> <li>• Royal College of Emergency Medicine</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for Cardiological Science and Technology</li> <li>• Society for Vascular Nurses</li> <li>• Society for Vascular Technology</li> <li>• UK Clinical Pharmacy Association</li> <li>• Vascular Society of Great Britain and Ireland</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• Health Technology Wales (HTW)</li> <li>• NHS England</li> </ul>	<ul style="list-style-type: none"> <li>• Cochrane Airways Group</li> <li>• Cochrane Heart Stroke and Circulation</li> <li>• Cochrane Vascular</li> <li>• European Council for Cardiovascular Research</li> <li>• Genomics England</li> <li>• Heart Research UK</li> <li>• MRC Clinical Trials Unit</li> <li>• National Centre for Cardiovascular Preventions and Outcomes</li> <li>• National Institute for Health Research</li> <li>• Wellcome Trust</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

## Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

## Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease ID6459

Issue date: March 2025

© National Institute for Health and Care Excellence 2025. All rights reserved. 2 of 3

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.